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synthesized and cloned in the composition of plasmid pcDNA3.1
that is eukaryotic expression vector. Accuracy of gene insertion
encoding polyepitopeimmunogen was verified using restriction
analysis. Obtained target plasmid pBC-A*0201 – candidate DNA-
vaccine was used for evaluation of gene expression in transfected
eukaryotic cells 293T and dendritic cells by means of flow cytoflu-
orometry and immunohistochemistry using MAT to p24 epitope-
marker inserted into the structure of target plasmid. Dendritic
cells were obtained from peripheral blood precursors by 2-h plas-
tic adhesion. The nonadherent cells were removed 2 h later and
the adherent monolayer was cultivated in the medium containing
growth factors (GM-CSF and IL-4) according to (Naik, 2010; Ganul
and Khranovskaya, 2012). Transfection of immature DCs (iDC)
was performed by using the reagents purchased from Promokine.
Further cultivation of iDCs was carried out in the medium con-
taining TNF- a to obtain fully mature DCs (mDC). Analysis of
mDCsurface markers expression was made using MAO (HLA-
DR, CD83, CD86) and flow cytofluorometer (BD FACSCalibur).
Results: Plasmid pBC-A*0201 encoding epitopes of breast can-
cer antigens was constructed and produced in preparative
amount. Using the method of intracellular staining of product
of expression by specific MAO 29F2 to epitope p24, we showed
expression of gene BC-A*0201 in eukaryotic cells 293T and
dendritic cells transfected by plasmid pBC-A*0201. Maturity of
dendritic cells was also proved.
Conclusion: Thus, obtained candidate DNA-vaccine encoding
target polyepitopeimmunogen provides synthesis of relevant
protein in the eukaryotic cells culture. In future, we plan to study
biological activity of DNA-vaccine to evaluate level of induction of
cytotoxic response against SKBR3 breast cancer cells.
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Differently sized microparticles, including exosomes (30–
100 nm), prostasomes (50–500 nm), oncosomes (50–500 nm) and
other microparticles (100–1000 nm) were found in blood and
urine. Exosomes from prostate cancer (PCa) patients can poten-
tially contain cancer-specific nucleic acids, and thus can repre-
sent a valuable source of diagnostic material. In this study, we
have investigated microvesicles and miRNA from urine of healthy
donors and PCa patients. To isolate miRNAs from urine and
microparticles, novel methods for miRNA isolation were elabo-
rated (Rus. patent application No 2014137763, priority date
17.09.2014). The study population included 14 patients with PCa
(63–82 years, T2-3NxMx1) and control group of 20 healthy
volunteers with no previous history of prostate disease
(48–73 years). Urine was clarified by two serial centrifugations at
400g, 20 C, 20 min and at 17000g, 20 C, 20 min. Microparticles
were precipitated from the resulting supernatant by high-speed
centrifugation at 100000g, 18 C, 90 min, the pellet was resus-
pended and pelleted by centrifugation under the same condi-
tions. To isolate exosomes, total microparticles were filtered
through 0.1 lm pore filters and reprecipitated. The resulting pel-
lets were resuspended and exosome samples were investigated
by transmission electron microscopy (TEM). MiRNAs were iso-
lated by one-step single-phase protocol and purified using ‘‘BioSil-
ica” spin- columns (Zaporozhchenko et al., Anal. Biochem,
upcoming, doi: 10.1016/j.ab.2015.03.028) and by recently devel-
oped method based on precipitation of excess biopolymers,
allowing to isolate miRNAs with better efficiency than commer-
cially available kits. The size and quantity assessment of extracel-
lular RNAwere performed using capillary electrophoresis system
on Agilent 2100 Bioanalyzer. Concentrations of miRNAs (miR19b,
miR25, miR205, miR125b, miR126) were measured by qRT-PCR and
normalized to miR-16 using dCq method.
TEM demonstrated the presence of 20–300 nm microparticles
in urine of healthy donors and PCa patients. Approximately
50–70% of all urine microparticles are represented by 30–100 nm
exosomes and residual 30–50% by particles larger than 100 nm.
(The pool of urine microvesicles consists of 50–70% exosomes
and 30–50% particles larger than 100 nm.).
The major part of extracellular RNA found both in exosomes
and total microparticles fraction of healthy donors and patients
with PCa, is 25–200 nt long and can include tRNA (73–93 n.), 5.8
rRNA (150 n.), snoRNK (10–20 n.), snRNA (60–300 n.) piRNAs
(29–30 n.), miRNAs (20–25 n.), siRNA (21–25 n.). Concentration of
extracellular urine RNA in exosomes and total microparticles of
healthy donors and patients with PCa amounts to100 pg/ml of
urine on average.Receiver Operating Characteristic (ROC) curve
analysis of all miRNAs in samples isolated from total urine did
not demonstrate any diagnostic significance. In contrast, in train-
ing cohort concentration of miR-19b in exosomes and total
microparticles fraction provide 95%/75% and 93%/100% sensitivity
and specificity, respectively.
Thus, microparticles, isolated from urine of PCa patients
represent a valuable source of diagnostically significant miRNAs.
To investigate miR-19b, a large testing cohort is required. Search
for other potential miRNA-markers by microarray profiling of
cell-free miRNA isolated from urine of PCa patients is also
required to reveal a sold set of markers for confident PCa
diagnostics.
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